Garrett T Graham

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2920490/publications.pdf

Version: 2024-02-01

471061 500791 1,206 29 17 28 citations h-index g-index papers 31 31 31 2675 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Comprehensive profiling of mRNA splicing indicates that GC content signals altered cassette exon inclusion in Ewing sarcoma. NAR Cancer, 2022, 4, zcab052.	1.6	5
2	An AIB1 Isoform Alters Enhancer Access and Enables Progression of Early-Stage Triple-Negative Breast Cancer. Cancer Research, 2021, 81, 4230-4241.	0.4	11
3	Clofarabine induces ERK/MSK/CREB activation through inhibiting CD99 on Ewing sarcoma cells. PLoS ONE, 2021, 16, e0253170.	1.1	2
4	Loss of ANCO1 repression at AIB1/YAP targets drives breast cancer progression. EMBO Reports, 2020, 21, e48741.	2.0	15
5	Sierra Nevada sweep: metagenomic measurements of bioaerosols vertically distributed across the troposphere. Scientific Reports, 2020, 10, 12399.	1.6	13
6	Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH. Cell Death and Differentiation, 2020, 27, 2143-2157.	5.0	60
7	Development of an Ewing sarcoma cell line with resistance to EWS‑FLI1 inhibitor YK‑4‑279. Molecular Medicine Reports, 2020, 21, 1667-1675.	1.1	2
8	EWS–FLI1 modulated alternative splicing of ARID1A reveals novel oncogenic function through the BAF complex. Nucleic Acids Research, 2019, 47, 9619-9636.	6.5	35
9	A Yap-Myc-Sox2-p53 Regulatory Network Dictates Metabolic Homeostasis and Differentiation in Kras-Driven Pancreatic Ductal Adenocarcinomas. Developmental Cell, 2019, 51, 113-128.e9.	3.1	50
10	Short- and Long-Term Effects of CDK4/6 Inhibition on Early-Stage Breast Cancer. Molecular Cancer Therapeutics, 2019, 18, 2220-2232.	1.9	7
11	The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells. Molecular Cancer Research, 2019, 17, 1815-1827.	1.5	40
12	The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents. Clinical Cancer Research, 2019, 25, 5167-5176.	3.2	43
13	Single-Molecule Real-Time (SMRT) Full-Length RNA-Sequencing Reveals Novel and Distinct mRNA Isoforms in Human Bone Marrow Cell Subpopulations. Genes, 2019, 10, 253.	1.0	16
14	Somatic mutation signatures in primary liver tumors of workers exposed to ionizing radiation. Scientific Reports, 2019, 9, 18199.	1.6	8
15	A Mechanism of Resistance to Antibody-Targeted Immune Attack. Cancer Immunology Research, 2019, 7, 230-243.	1.6	39
16	The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. Cell Death and Differentiation, 2018, 25, 1239-1258.	5.0	81
17	Reprint of: Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. Cancer Genetics, 2018, 228-229, 131-142.	0.2	5
18	Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors. Science, 2018, 361, .	6.0	121

#	Article	IF	CITATIONS
19	Prevention of Lipid Peroxidation–derived Cyclic DNA Adduct and Mutation in High-Fat Diet–induced Hepatocarcinogenesis by Theaphenon E. Cancer Prevention Research, 2018, 11, 665-676.	0.7	9
20	Inhibition of the oncogenic fusion protein EWS-FLI1 causes G ₂ -M cell cycle arrest and enhanced vincristine sensitivity in Ewing's sarcoma. Science Signaling, 2017, 10, .	1.6	51
21	Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. Cancer Genetics, 2017, 218-219, 39-50.	0.2	42
22	Ezrin Inhibition Up-regulates Stress Response Gene Expression. Journal of Biological Chemistry, 2016, 291, 13257-13270.	1.6	40
23	Rac1-Mediated DNA Damage and Inflammation Promote Nf2 Tumorigenesis but Also Limit Cell-Cycle Progression. Developmental Cell, 2016, 39, 452-465.	3.1	23
24	RNA helicase A activity is inhibited by oncogenic transcription factor EWS-FLI1. Nucleic Acids Research, 2015, 43, 1069-1080.	6.5	30
25	Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1307-16.	3.3	109
26	Multifactorial Analysis of Conditional Reprogramming of Human Keratinocytes. PLoS ONE, 2015, 10, e0116755.	1.1	18
27	Cellular Reprogramming of Epithelial Cells Leading to Conditional Immortalization is Accompanied by Changes in Multiple Pathways. FASEB Journal, 2015, 29, 670.6.	0.2	O
28	PBX1 Is a Favorable Prognostic Biomarker as It Modulates 13- <i>cis</i> Retinoic Acid–Mediated Differentiation in Neuroblastoma. Clinical Cancer Research, 2014, 20, 4400-4412.	3.2	22
29	Downstream of Mutant KRAS, the Transcription Regulator YAP Is Essential for Neoplastic Progression to Pancreatic Ductal Adenocarcinoma. Science Signaling, 2014, 7, ra42.	1.6	307